research use only

Bardoxolone (CDDO) Nrf2 activator

Name: Bardoxolone (CDDO)
Brand: Selleck Chemicals
SKU: S6647
Availability: InStock
Rating: 5 (8 reviews)

Cat.No.S6647

Bardoxolone (CDDO), acts by releasing Nrf2 from KEAP1,is a highly potent activator of Nrf2 that induce programmed cell death (apoptosis) in cancer cells.

Bardoxolone (CDDO) Nrf2 activator Chemical Structure

Quality Control

Batch: S664701 DMSO]6 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 98.45%

Cited in Nature Medicine for its top-tier quality
COA
HPLC
SDS/MSDS
Datasheet

98.45

Related Targets	PD-1/PD-L1 CXCR STING AhR Immunology & Inflammation related CD markers Interleukins Anti-infection Antioxidant COX
Other Nrf2 Inhibitors	Bardoxolone Methyl (RTA 402) ML385 Sulforaphane Brusatol TBHQ Oltipraz 4-Octyl Itaconate (4-OI) KI696 CDDO-Im (RTA-403) Mangiferin

Solubility

In vitro
Batch:

DMSO : 6 mg/mL (12.2 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.300mg/ml (0.61mM)	Taking the 1 mL working solution as an example, add 50 μL of 6 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.300mg/ml (0.61mM)	Taking the 1 mL working solution as an example, add 50 μL of 6 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	491.66	Formula	C₃₁H₄₁NO₄	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	218600-44-3	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	RTA 401			SMILES	CC1(CCC2(CCC3(C(C2C1)C(=O)C=C4C3(CCC5C4(C=C(C(=O)C5(C)C)C#N)C)C)C)C(=O)O)C

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	Nrf2
References	[1] https://www.ncbi.nlm.nih.gov/pubmed/?term=29371416

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2025-06-03)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03749447	TERMINATED	Chronic Kidney Diseases; Alport Syndrome; Autosomal Dominant Polycystic Kidney	Biogen	2019-03-08	PHASE3
NCT03918447	TERMINATED	Autosomal Dominant Polycystic Kidney; ADPKD	Biogen	2019-05-29	PHASE3
NCT03550443	TERMINATED	Diabetic Kidney Disease	Kyowa Kirin Co., Ltd.	2018-05-30	PHASE3
NCT04702997	COMPLETED	Chronic Kidney Diseases	Biogen	2021-02-09	PHASE2
NCT04494646	COMPLETED	Covid19	NYU Langone Health	2020-09-08	PHASE2
NCT03019185	COMPLETED	Alport Syndrome	Biogen	2017-03-02	PHASE2; PHASE3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):